Sheheryar Kabraji

Associate Professor

Roswell Park Comprehensive Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Sheheryar Kabraji is an Associate Professor at Roswell Park Cancer Institute in the United States. His research focuses on innovative therapeutic strategies for breast cancer and colorectal cancer, particularly in the context of HER2-targeted therapies and immune evasion mechanisms. Recent articles include investigations into trastuzumab deruxtecan efficacy in HER2-positive breast cancer and the role of RAS/RAF mutations in therapy responsiveness.

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (6)

Hersh Gupta

Dana-Farber Cancer Institute

UNITED STATES

View details

Liya Ding

Assistant Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES

View details

Myles Brown

Professor of Medicine

Dana-Farber Cancer Institute

UNITED STATES

View details

Steven Corsello

Stanford University

UNITED STATES

View details

Sarah Sammons

Assistant Professor

Dana-Farber Cancer Institute

UNITED STATES

View details

Qiwei Wang

Assistant Professor

University of Virginia

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Sheheryar Kabraji

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Results of a patient-level pooled analysis of three studies of trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastasis

Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer

RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases

Keeping It in the Family: HER3 as a Target in Brain Metastases

PI3Kβ controls immune evasion in PTEN-deficient breast tumours

STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer

p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases

Temporal and spatial topography of cell proliferation in cancer

Integrating immunotherapy and targeted therapy in cancer treatment: Mechanistic insights and clinical implications

Collaborators (6)

Hersh Gupta

Liya Ding

Myles Brown

Steven Corsello

Sarah Sammons

Qiwei Wang

Make your next move.